nature portfolio

Corresponding author(s):	José Cerca, Michael D. Martin
Last updated by author(s):	Dec 8, 2021

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For	all st	tatistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.	
n/a	Confirmed		
	×	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement	
x		A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly	
	×	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.	
x		A description of all covariates tested	
	×	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons	
	×	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)	
	×	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>	
X		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings	
X		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes	
X		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated	
		Our walk collection an statistics for highesists contains articles an many of the points above	

Software and code

Policy information about <u>availability of computer code</u>

Data collection

No software used.

Genome assembly - wtdbg2
Genome decontamination - Blobtools v1.1.1
Duplicates - purge_dups v1.1.2
Scaffolding - HiRise v1

Genome assessment - Assemblathon2, BUSCO viridiplantae odb v10
Repeat identification - RepeatMasker v4.1.1, RepeatModeler v2.0.1

RNA data processing - lima v2.0.0, Isoseq3 refine v3.4.0, Isoseq3 cluster v3.4.0, pbmm2 align v1.4.0, SQANTI3 v1.0.0

Gene annotation - MAKER2 pipeline v2.31.9

 $Re-sequencing\ data\ processing\ and\ demography-FastQC\ v0.11.8,\ Adapter Removal\ v2.3.1,\ Trimmomatic\ v0.39,\ bwa\ mem\ 0.7.17,\ PSMC\ v0.6.5$

COS processing - phyluce v1.6.8 k-mer processing - Jellyfish v0.8.9 Circos plots - circos v0.69.8

Orthology - Blast v2.12, OrthoFinder v2.5.4

Selection and gene expansions - CAFE v4.2.1, hyphy v2.5.3.

TopGO 2.46.0

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about <u>availability of data</u>

Clinical data

Dual use research of concern

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The raw data generated in this study have been deposited in the ENA database under accession code https://www.ebi.ac.uk/ena/browser/view/PRJEB52418. The assembly and the annotation files are available here https://datadryad.org/stash/dataset/doi:10.5061/dryad.8gtht76rh.

Field-specific reporting				
·	w that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
Life sciences	Behavioural & social sciences			
For a reference copy of the docum	nent with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>			
Ecological, evolutionary & environmental sciences study design				
All studies must disclose on these points even when the disclosure is negative.				
Study description	We sequenced a genome, using long reads and contiguity-ligation methods. Using this assembly we estimated natural selection, demography, gene-family evolution and subgenome estimation.			
Research sample	We sequenced a genome from a plant and obtained RNA from the same individual for reproducibility. We added some closely related species for demographic analyses. Scalesia atrctyloides was selected because it is critically endangered and has low genomic heterozygosity suitable for de-novo assembly.			
Sampling strategy	Not applicable			
Data collection	DNA was obtained from leaves, RNA from various tissues (flower, leaf early development, leaf late development, root, stem)			
Timing and spatial scale	Not applicable			
Data exclusions	No data was removed			
Reproducibility	The code is available in https://github.com/jcerca/Papers/tree/main/scalesia_genome , and has been double-checked for reproducibility.			
Randomization	Not applicable for genome data.			
Blinding	Not applicable for genome data			
Did the study involve field work? Yes X No				
Reporting for specific materials, systems and methods				
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.				
Materials & experimental systems Methods				
n/a Involved in the study n/a Involved in the study				
X ChIP-seq				
Eukaryotic cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Continuous cell lines Conti				
Animals and other organisms				
Human research participants				